Compare MEC & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MEC | CBIO |
|---|---|---|
| Founded | 1945 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 527.1M | 488.1M |
| IPO Year | 2019 | 2013 |
| Metric | MEC | CBIO |
|---|---|---|
| Price | $15.76 | $12.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $37.00 | $31.50 |
| AVG Volume (30 Days) | ★ 406.4K | 287.1K |
| Earning Date | 11-03-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $18,500.00 |
| Revenue This Year | $16.40 | N/A |
| Revenue Next Year | $14.08 | $177.36 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.42 | $8.72 |
| 52 Week High | $38.76 | $27.41 |
| Indicator | MEC | CBIO |
|---|---|---|
| Relative Strength Index (RSI) | 53.56 | 41.73 |
| Support Level | $14.36 | $11.78 |
| Resistance Level | $18.84 | $13.54 |
| Average True Range (ATR) | 0.85 | 0.99 |
| MACD | 0.39 | 0.20 |
| Stochastic Oscillator | 86.12 | 34.81 |
Mayville Engineering Co Inc is involved in a manufacturing partner providing a full suite of manufacturing solutions from concept to production, including design, prototyping and tooling, fabrication, aluminum extrusion, coating, assembly, and aftermarket components. Its customers operate in diverse end markets, including heavy- and medium-duty commercial vehicles, construction, powersports, agriculture, military, and other end markets. Its services comprise stamping, shearing, fiber laser cutting, forming, drilling, tapping, grinding, tube bending, machining, welding, assembly, and logistic services.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.